Attovia Therapeutics Lists on NASDAQ under Ticker ATTO: Is This Biparatopic Biotech Worth Bidding?
Attovia Therapeutics (NASDAQ: ATTO) debuts raising $200 Million. Discover its biparatopic antibody platform, clinical trial timelines, and SWOT analysis.
